Navigation Links
Kiadis Pharma Continues to Provide Rhitol to Participating Physicians During Completion of Current Clinical Study
Date:11/19/2007

AMSTERDAM, November 19 /PRNewswire/ -- Kiadis Pharma announced today that it has agreed to provide Rhitol during a limited period of time to requesting physicians participating in the ongoing phase I/II trial. The Rhitol phase I/II trial is closed for enrolment to treat new patients and is expected to complete at the end of this year. Kiadis Pharma anticipates applying for and starting a phase III study in 2008.

Manja Bouman, CEO Kiadis Pharma commented: "We realised that the sites participating in the ongoing phase II trial were left without treatment alternatives following the announcement of the enrolment closure. The interest these physicians show in using our product for new patients is very encouraging and we are very pleased that we can support them by providing Rhitol through special provisions, until the start of the phase III clinical trial."

The physicians interested in enabling new patients to receive treatment with Rhitol will obtain regulatory authorization from the appropriate agency to allow for compassionate use of Rhitol.

Rhitol is under development for patients with severe chronic steroid refractory Graft versus Host Disease (GvHD) who have exhausted other treatment options. Chronic GvHD is a condition that can develop after allogeneic bone marrow transplantation and resembles an autoimmune disease. The immune cells from the donor graft cause GvHD by attacking the patient's tissues and organs. There are two forms of GvHD: acute GvHD appears within 100 days after transplantation and chronic GvHD begins anytime after that period. Immune-suppressant drugs, such as steroids, are generally used to treat chronic GvHD. The disease can become a life-threatening condition when standard treatment cannot control its progression as the patient either does not respond to steroid treatment or develops severe side effects due to their use. Extensive chronic GvHD affects multiple organs and tissues and results in diminished quality of lif
'/>"/>

SOURCE Kiadis Pharma B.V.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Kiadis Pharma Announces ATIR Interim Clinical Results
2. FDA Grants Kiadis Pharma Lead Product ATIR Orphan Drug Designation
3. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
4. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
5. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
8. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
10. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
11. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... July 25, 2014 Newyorktermlifeinsurance.org has ... life insurance plans and traditional policies. , The ... clients make between no medical exam life insurance plans ... types of life insurance plans to provide a simple ... life insurance plans can now be purchased online. Although ...
(Date:7/25/2014)... July 25, 2014 CarePoint Health is ... Edward Boylan, has joined our network, CarePoint Health Medical ... Hundreds of highly skilled and experienced physicians comprise CarePoint ... and practices in Hudson County, representing a wide range ... to provide the highest quality care to patients and ...
(Date:7/25/2014)... Rockville Centre, NY (PRWEB) July 25, 2014 ... national personal injury law firm with over 25 ... of harm stemming from dangerous prescription drugs, announces ... , to offer information to those who believe ... Xarelto. , The site offers valuable information ...
(Date:7/25/2014)... TX (PRWEB) July 25, 2014 ... Outlook to 2020” provides company shares and distribution ... and global corporate-level profiles of the key market ... to the Laryngoscopes market wherever available. , The ... market forecast models. Rsearcher uses epidemiology and capital ...
(Date:7/25/2014)... Although cervical cancers are declining in the United States ... are increasing, a new study indicates. HPV-related cancers ... and tonsils have increased over the past 35 years, ... Canadian researchers report. "The increases in the incidence ... anal cancer among younger women are disturbing, because there ...
Breaking Medicine News(10 mins):Health News:No Medical Exam Life Insurance and Traditional Plans - Newyorktermlifeinsurance.org Provides Quotes for All Types of Life Insurance 2Health News:Dr. Boylan Joins CarePoint Health Medical Group 2Health News:Rottenstein Law Group LLP Announces Launch of Xarelto Injury Website 2Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 2Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 3Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 4Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 5Health News:Anal, Throat Cancers on the Rise Among Young Adults, Study Finds 2
... In a study of 14 adults with histories of ... not appear// to have effects that indicate potential for ... report in the October issue of Archives of General ... to 15 percent of adults regularly experience chronic insomnia, ...
... the time, they are nothing but a cosmetic nuisance. ... dividing abnormally to form a deadly form of skin ... this year will be diagnosed with melanoma at some ... percent of all melanomas begin in a mole. They ...
... of Nutrition in its current issue (October) has published ... Cookies TM can not only lower cholesterol levels but ... This would substantially curtail the risk of cardiac disease. ... purposes taken from the common fleawort, proven to be ...
... Health and Clinical Excellence (Nice) has planned new guidelines ... (porous bones) are at higher risk of fractures. The ... fragile bones. ,Post menopausal women at any ... wants to execute guidelines according to which, only women ...
... World Action on Salt and Health has been launched today ... 2.5 million deaths a year.// ,194 medical experts in ... companies into reducing dietary salt intake to prevent high blood ... a World Health Organisation summit in Paris to discuss the ...
... research proposes that the drug used to treat wet age-related ... vision in some people. // ,Wet AMD is the ... can be regained to some extent in people with a ... drug Lucentis. ,The study was published in the ...
Cached Medicine News:Health News:New Sleep Medication not Effective for Treating Abuse or Cognitive Impairment 2Health News:New Sleep Medication not Effective for Treating Abuse or Cognitive Impairment 3Health News:Why Don’t All Moles Progress to Melanoma 2Health News:Why Don’t All Moles Progress to Melanoma 3Health News:Chocolate Chip Cookies to Keep Cholesterol at Bay 2Health News:Food Makers Pressurized to Reduce Salt 2Health News:Vision restoration with a drug for macular degeneration 2
(Date:7/24/2014)... CITY, Calif. , July 24, 2014   ... specialty pharmaceutical company focused on the development and commercialization ... breakthrough pain, today confirmed the PDUFA date for Zalviso ... learned that a rumor circulated online stating the Food ... July 24, 2014 there has been no notification to ...
(Date:7/24/2014)... , and MARSEILLE, France , ... , Exclusive global license from University of Tokyo enables ... sequencing (NGS) gene panels, for blood cancers  ... test, indicate favorable prognosis for patients with bone marrow ... potential for developing companion diagnostics to guide treatment with ...
(Date:7/24/2014)... Amgen (NASDAQ: AMGN ) today announced ... Tuesday, July 29, 2014, after the close of the U.S. ... call with the investment community at 2 p.m. PT. Participating ... Bradway , chairman and chief executive officer, and other members ... the conference call will be simultaneously broadcast over the Internet ...
Breaking Medicine Technology:AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Amgen Announces Webcast of 2014 Second Quarter Financial Results 2
The EK-H Series offer 10 selectable units of measure...
Digital Thermometer & High-Low Temp Alarm, -50C to +90C...
Thermometer for Round Water Bath...
... Digital Thermostat and Digital Display. , Exterior300 ... , Interiorwhite anodized aluminum with 300 ... refrigeration (134A). , Temperature range 0C ... doors. , Foamed-in-place polyurethane high density ...
Medicine Products: